Sana Biotechnology Announces Positive Clinical Results From Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
Sana Biotechnology released what it assessed as positive data from a study of its in-development treatment for type 1 diabetes. The company said it transplanted its treatment, UP421, an allogeneic primary islet cell therapy engineered with its hypoimmune technology, into a patient with type 1 diabetes without the use of any immunosuppression. The study identified no safety issues, and the hypoimmune-modified islet cells evaded immune responses.